These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23179812)

  • 21. Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film.
    Sedlak L; Wojnar W; Zych M; Wyględowska-Promieńska D
    Cutan Ocul Toxicol; 2020 Sep; 39(3):260-268. PubMed ID: 32594785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
    Levrat F; Pisella PJ; Baudouin C
    J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials.
    Trocme S; Hwang LJ; Bean GW; Sultan MB
    Ann Pharmacother; 2010 Dec; 44(12):1914-21. PubMed ID: 21119099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antiglaucoma drugs--content of preservatives and the patient's compliance].
    Výborný P; Sejcková L
    Cesk Slov Oftalmol; 2006 Jul; 62(4):270-2, 274. PubMed ID: 16895060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular benzalkonium chloride exposure: problems and solutions.
    Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
    Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of common ophthalmic preservatives on ocular health.
    Noecker R
    Adv Ther; 2001; 18(5):205-15. PubMed ID: 11783457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye.
    De Saint Jean M; Debbasch C; Brignole F; Warnet JM; Baudouin C
    Adv Exp Med Biol; 2002; 506(Pt A):697-702. PubMed ID: 12613979
    [No Abstract]   [Full Text] [Related]  

  • 29. Ophthalmic preservatives: focus on polyquaternium-1.
    Rolando M; Crider JY; Kahook MY
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1425-38. PubMed ID: 21905766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRESERVATIVES FROM THE EYE DROPS AND THE OCULAR SURFACE.
    Coroi MC; Bungau S; Tit M
    Rom J Ophthalmol; 2015; 59(1):2-5. PubMed ID: 27373107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops.
    Inoue D; Mohamed YH; Uematsu M; Kitaoka T
    Cutan Ocul Toxicol; 2020 Jun; 39(2):158-164. PubMed ID: 32295438
    [No Abstract]   [Full Text] [Related]  

  • 33. [Conditions bordering on allergy].
    Baudouin C
    J Fr Ophtalmol; 2007 Mar; 30(3):306-13. PubMed ID: 17417159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjunctival markers as predictable markers for preoperative glaucoma assessment.
    Pisella PJ
    Br J Ophthalmol; 2006 Nov; 90(11):1335-6. PubMed ID: 17057168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride.
    Wang YQ; Wang X; Liu P
    Asian Pac J Trop Med; 2013 Dec; 6(12):1004-8. PubMed ID: 24144037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated high-throughput drug screening microfluidic system for comprehensive ocular toxicity assessment.
    Cho K; Lee J; Kim J
    Toxicol In Vitro; 2024 Jun; 98():105843. PubMed ID: 38735502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A correct understanding of preservatives in eye drops].
    Liu Z; Huang C
    Zhonghua Yan Ke Za Zhi; 2015 Sep; 51(9):641-4. PubMed ID: 26693647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glaucoma therapy and ocular surface disease: current literature and recommendations.
    Anwar Z; Wellik SR; Galor A
    Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease.
    Zhang R; Park M; Richardson A; Tedla N; Pandzic E; de Paiva CS; Watson S; Wakefield D; Di Girolamo N
    Ocul Surf; 2020 Jan; 18(1):158-169. PubMed ID: 31740391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unilateral drug-induced ocular pseudopemphigoid.
    Gibran SK
    Eye (Lond); 2004 Dec; 18(12):1270. PubMed ID: 15044940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.